TCTR20170719004尚未招募1 期
Bioequivalence Study of 10 mg Ezetimibe Tablet Preparations in Healthy Thai Volunteers
Bio-innova and Synchron.Co.,Ltd0 个研究点目标入组 40 人开始时间: 2017年7月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy Thai male/female subjects between the ages of 18 to 55 years.
- •2.Body mass index between 18.0 to 25.0 kg/m2.
- •3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study.
- •4.Non-pregnant woman (negative pregnancy test) and not currently breast feeding.
- •5.Female subjects abstain from oral contraception for at least 28 days prior to admission in Period 1. Injectable contraceptives e.g. Depo-Provera® must be discontinued at least 6 months. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to admission in Period 1 until 7 days after the end of study.
- •6.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence during study period.
- •7.Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •8.Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
排除标准
- •1.History of allergic reaction or hypersensitivity to ezetimibe or related structure or any of the components of the product.
- •2.History or evidence of clinically significant hepatic, renal, seasonal allergies, endocrine e.g. thyroid or any condition possibly affecting drug bioavailability or had gastrectomy, enterectomy, gastritis, duodenal or gastric ulceration other than appendectomy.
- •3.History of treatment for severe acute or chronic disease or had an intensity of abnormal laboratory results which could be increased the risks relative to participant in the study or volunteers are inappropriate to attend the study due to obtain investigational products that may affect the interpretation of the results of research, however, these must be under consideration of clinical investigator.
- •4.Investigation with blood sample shows positive test for HBsAg or HCVAb.
- •5.History of fever within 1 week prior to admission in each period.
- •6.History of severe diarrhea or vomiting within 1 week prior to admission in each period.
- •7.History of abnormal muscle disease, myalgia, rhabdomyolysis, muscle tenderness or myopathy.
- •8.History of chronic alcohol consumption or drug addict.
- •9.Abnormal liver function, ≥ 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test.
- •10.Abnormal Creatinine phosphokinase, ≥ 3 times of upper normal limit of reference range at screening laboratory test (not because of exercise).
- •11.12-lead ECG demonstrating QTc >450 msec, a QRSD interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRSD exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRSD values should be used to determine the subject’s eligibility.
- •12.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period.
- •13.History or evidence of alcoholism, regular alcohol consumption or alcohol-containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period.
- •14.History or evidence of habitual consume of tea, coffee, xanthine or caffeine containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period.
- •15.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (Marijuana (THC), cocaine, opioids, amphetamines or benzodiazepines).
- •16.Use of prescription or nonprescription drugs within 14 days prior to admission in Period 1 especially any drugs which affect the metabolizing enzyme such as erythromycin, ketoconazole, except acetaminophen (paracetamol) ≤ 1 g/day.
- •17.Use of herbal medications or supplements especially St. John’s wort (Hypericum perforatum), vitamin or dietary supplements and cannot abstain for at least 14 days prior to admission and continued until last sample collection in each study period.
- •18.Consume or drink juice of grapefruit or orange or its supplement/ containing products and cannot abstain for at least 14 days prior to admission and continued until last sample collection in each study period.
研究者
相似试验
Unknown
1 期
Bioequivalence of Ezetimibe Tablets in Healthy SubjectsTherapeutic EquivalencyNCT04814589Cao Yu96
已完成
1 期
Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy SubjectsHyperlipidemiasNCT05681247The Affiliated Hospital of Qingdao University59
已完成
Unknown
Bioequivalence evaluation of Azithromycin Tablet 100 mg of Mahban Pharmaceutical companyIRCT20200625047913N10Hezareh Sevom Futuristic Pharmacist24
已完成
不适用
Assessment of efficacy and safety of ezetimibe in patients with dyslipidemia complicated insulin resistance.Dyslipidemia complicated insulin resistanceJPRN-UMIN000005775The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University Hospital47
已完成
1 期
Bioequivalence Study of Generic Simvastatin/ Ezetimibe 20/10 mg TabletHealthy subjectsbioequivalence studygenericSimvastatin/ Ezetimibe 20/10 mg TabletTCTR20230620003Duopharma Biotech Berhad52